Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Pitkäaikainen tutkimus lääketieteestä, jota kutsutaan Abrosiinibiksi 2-vuotiailla ja sitä vanhemmilla lapsilla, ja kohtalainen tai vaikea ihottuma

tiistai 3. marraskuuta 2026 päivittänyt: Pfizer

Vaiheen 3, monikeskus, pitkäaikainen, avoin tarratutkimus, jossa arvioidaan abrocitinibin turvallisuutta ja tehokkuutta, ja sitä vanhemmille ja sitä vanhemmille lasten osallistujille annetuille ajankohtaisille lääkkeille tai ilman sitä, ja atooppinen ihottuma on kohtalainen tai vaikea

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Phase 3, open-label study to assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children ≥2 years of age with moderate-to-severe atopic dermatitis (AD). This study will enroll participants in two cohorts: an extension cohort of participants who previously completed prior abrocitinib studies, and a de novo cohort of participants (6 to <12 years of age) who have not participated in previous abrocitinib studies. Study duration will be up to 2 years (or commercial availability, whichever occurs earlier). The study will enroll a maximum of approximately 500 participants with moderate-to-severe Atopic Dermatitis from study sites globally (extension cohort will enroll up to 320 participants; de novo cohort will enroll approximately 180 participants). All participants will receive the study intervention abrocitinib oral suspension.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

450

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Zaragoza, Espanja, 50009
        • Rekrytointi
        • Hospital Universitario Miguel Servet
    • A Coruña [LA Coruña]
      • Santiago de Compostela, A Coruña [LA Coruña], Espanja, 15706
        • Rekrytointi
        • CHUS - Hospital Clinico Universitario
    • Barcelona
      • Granollers, Barcelona, Espanja, 08402
        • Rekrytointi
        • Hospital General de Granollers
      • Fukuoka, Japani, 811-1394
        • Rekrytointi
        • Fukuoka National Hospital
      • Fukuoka, Japani, 819-0042
        • Rekrytointi
        • Saruta Dermatology Clinic
    • Kanagawa
      • Yokohama, Kanagawa, Japani, 220-6208
        • Rekrytointi
        • Queen's square Medical Facilities Queen's square Dermatology and Allergology
    • Osaka
      • Sakai, Osaka, Japani, 593-8324
        • Rekrytointi
        • Dermatology and Ophthalmology Kume Clinic
    • Tokyo
      • Setagaya-ku, Tokyo, Japani, 157-0066
        • Rekrytointi
        • Sasamoto Children's Clinic
      • Shanghai, Kiina, 200062
        • Rekrytointi
        • Shanghai Children's Hospital
      • Shanghai, Kiina, 200092
        • Rekrytointi
        • Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kiina, 100045
        • Rekrytointi
        • Beijing Children's hospital, Capital Medical University
    • Guangdong
      • Shenzhen, Guangdong, Kiina, 518026
        • Rekrytointi
        • Shenzhen Children's Hospital
    • Hunan
      • Changsha, Hunan, Kiina, 410007
        • Rekrytointi
        • Hunan Children's Hospital
    • Jiangxi
      • Nanchang, Jiangxi, Kiina, 330000
        • Ei vielä rekrytointia
        • Dermatology Hospital of Jiangxi Province
    • Zhejiang
      • Hangzhou, Zhejiang, Kiina, 310009
        • Rekrytointi
        • Hangzhou Third People's Hospital
      • Chihuahua City, Meksiko, 31238
        • Ei vielä rekrytointia
        • Servicios Hospitalarios de Mexico S.A. DE C.V.
    • Mexico City
      • Mexico City, Mexico City, Meksiko, 06720
        • Ei vielä rekrytointia
        • Hospital Infantil de Mexico Federico Gomez
    • Nuevo León
      • Monterrey, Nuevo León, Meksiko, 64718
        • Ei vielä rekrytointia
        • Eukarya Pharmasite S.C.
    • Veracruz Ignacio de LA Llave
      • Veracruz, Veracruz Ignacio de LA Llave, Meksiko, 91900
        • Ei vielä rekrytointia
        • Arké SMO S.A de C.V
    • Lesser Poland Voivodeship
      • Krakow, Lesser Poland Voivodeship, Puola, 30-002
        • Rekrytointi
        • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
    • Lublin Voivodeship
      • Lublin, Lublin Voivodeship, Puola, 20-573
        • Rekrytointi
        • LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
    • Masovian Voivodeship
      • Warsaw, Masovian Voivodeship, Puola, 02-625
        • Rekrytointi
        • Centrum Medyczne Evimed
    • Silesian Voivodeship
      • Chorzów, Silesian Voivodeship, Puola, 41-500
        • Rekrytointi
        • DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
    • Łódź Voivodeship
      • Lodz, Łódź Voivodeship, Puola, 90-436
        • Rekrytointi
        • Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
    • Świętokrzyskie Voivodeship
      • Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Puola, 27-400
        • Rekrytointi
        • Dermedic Jacek Zdybski
    • Baranya
      • Pécs, Baranya, Unkari, 7632
        • Rekrytointi
        • Pécsi Tudományegyetem Klinikai Központ
    • Bekes County
      • Békéscsaba, Bekes County, Unkari, 5600
        • Rekrytointi
        • Trial Pharma Kft.
    • Csongrád-csanád
      • Szeged, Csongrád-csanád, Unkari, 6720
        • Ei vielä rekrytointia
        • University of Szeged
    • Pest County
      • Budapest, Pest County, Unkari, 1033
        • Rekrytointi
        • Clinexpert Kft.
    • Alabama
      • Birmingham, Alabama, Yhdysvallat, 35244
        • Rekrytointi
        • Cahaba Dermatology & Skin Health Center
    • Arkansas
      • North Little Rock, Arkansas, Yhdysvallat, 72117
        • Rekrytointi
        • Arkansas Research Trials
    • California
      • San Diego, California, Yhdysvallat, 92123
        • Rekrytointi
        • Investigational Drug Service - Rady Childrens Hospital-San Diego
      • San Diego, California, Yhdysvallat, 92123
        • Rekrytointi
        • University of California, San Diego/ Rady Children's Hospital - San Diego
    • Florida
      • Jacksonville, Florida, Yhdysvallat, 32256
        • Rekrytointi
        • Solutions Through Advanced Research
    • Idaho
      • Meridian, Idaho, Yhdysvallat, 83646
        • Rekrytointi
        • Ada West Research - Meridian
    • Indiana
      • Indianapolis, Indiana, Yhdysvallat, 46250
        • Rekrytointi
        • Dawes Fretzin Clinical Research Group, LLC
    • Missouri
      • St Louis, Missouri, Yhdysvallat, 63104
        • Rekrytointi
        • Saint Louis University
    • South Carolina
      • Charleston, South Carolina, Yhdysvallat, 29425
        • Rekrytointi
        • Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
      • Greenville, South Carolina, Yhdysvallat, 29607
        • Rekrytointi
        • Tribe Clinical Research, LLC
    • Texas
      • San Antonio, Texas, Yhdysvallat, 78235
        • Rekrytointi
        • Texas Dermatology and Laser Specialists

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

2 vuotta - 11 vuotta (Lapsi)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria for the Extension Cohort:

1. Participants who have completed the treatment phase of the qualifying parent study (age 2 to <12 years old).

• No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention.

Inclusion Criteria for the De Novo Cohort:

Age

  1. Children aged 6 to <12 years at the time of informed consent/assent.

    • No contraception methods are required for male participants.

    Disease Characteristics:

  2. Participants who meet all of the following AD criteria:

    • A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and
    • A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
    • Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy.

    Other Inclusion Criteria:

  3. Body weight ≥15 kg

Exclusion Criteria for the Extension Cohort:

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

    Prior/Concomitant Therapy:

  2. Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol.

  3. Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment.

    Diagnostic Assessments:

  4. Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria.

  5. Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern.

Exclusion Criteria for the De Novo Cohort

Medical Conditions:

  1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.

  2. Have any of the following medical conditions:

    • Infections:

      • Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1.
      • History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
      • Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
      • Infection with HIV, hepatitis B, and/or hepatitis C
      • Evidence of active TB or inadequately treated latent TB.
    • Skin Conditions:

      - Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.

    • Other Conditions:

      • Documented history of skeletal dysplasia.
      • Documented history of retinal detachment.
      • History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
      • Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
      • Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
      • Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.

    Prior/Concomitant Therapy:

  3. Prior treatment with a systemic JAK inhibitor for AD.

  4. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.

  5. Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study.

    Prior/Concurrent Clinical Study Experience:

  6. Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

    Diagnostic Assessments:

  7. Hepatic and/or renal and/or hematological abnormalities defined as:

    • AST >2 x ULN
    • Hemoglobin <10 g/dL
    • ALT >2 x ULN
    • ANC <1000/mm3
    • Total bilirubin ≥1.5 x ULN
    • ALC <500/mm3
    • eGFR <60 mL/min/1.73 m2
    • Platelets <150,000 /mm3

    Other Exclusion Criteria:

  8. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Ei satunnaistettu
  • Inventiomalli: Yksittäinen ryhmätehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Extension

Patients who have completed other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

Muut nimet:
  • PF-04965842
Kokeellinen: De novo

Patients who have not participated other abrocitinib studies

Abrocitinib administered as liquid oral suspension.

Muut nimet:
  • PF-04965842

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and adverse events (AEs) that lead to study discontinuation
Aikaikkuna: 0-24 months

The number of the treatment emergent adverse events, serious adverse events and adverse events leading to discontinuation among patients with moderate-to-severe disease treated with abrocitinib regardless of discontinuation from study treatment.

0-24 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants With Clinically Significant Laboratory Abnormalities
Aikaikkuna: 0-24 months

The number of clinically significant laboratory abnormalities among participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a 2 -point reduction from baseline at all scheduled time points
Aikaikkuna: Baseline, 24 months

Proportion of responders based on vIGA at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

Baseline, 24 months
Percentage of Response based on achieving a ≥4 point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at all scheduled time points in participants aged ≥2 to <6 years
Aikaikkuna: 0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WI-NRS (in patients aged ≥2 to <6 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Response based on achieving a ≥4-point improvement from baseline in the WSI-NRS at all scheduled time points in participants aged ≥6 to 12 years
Aikaikkuna: 0-24 months

Percentage of responders based on achieving an improvement ≥4 points from baseline at all scheduled time points in the WSI-NRS (in patients aged ≥6 to 12 years) with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Responders based on achieving Eczema Area and Severity Index (EASI)-50, EASI-90 and EASI-100 at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib
Aikaikkuna: 0-24 months

Percentage of response based on achieving ≥50%, ≥90%, 100% improvement from parent study baseline in the EASI total score (EASI-50, EASI-90, EASI-100) at all scheduled time points.

0-24 months
Percent Change from Baseline (CFB) in EASI total score at all scheduled time points.
Aikaikkuna: 0-24 months

Mean percent CFB in EASI total score at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
Percentage of Participants with Flares
Aikaikkuna: 0-24 months

Percentage of participants reporting flares in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in the percentage Body Surface Area (BSA) affected at all scheduled time points
Aikaikkuna: 0-24 months

Mean CFB in BSA affected at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Children's Dermatology Life Quality Index (CDLQI) at all scheduled time points.
Aikaikkuna: 0-24 months

Mean CFB in CDLQI at all scheduled time points in participants aged ≥4 to <16 years with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in in Infants' Dermatitis Quality of Life (IDQOL) Index at all scheduled time points
Aikaikkuna: 0-24 months

Mean CFB in IDQOL Index or CDQLI depending on age at all scheduled time points in participants aged <4 years with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in Patient-Oriented Eczema Measure (POEM) at all scheduled time points
Aikaikkuna: 0-24 months

Mean CFB in POEM at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Dermatitis Family Impact (DFI) at all scheduled time points
Aikaikkuna: 0-24 months

Mean CFB in DFI at all scheduled time points in participants with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Patient Global Impression of Severity (PGIS) at all scheduled time points
Aikaikkuna: 0-24 months

Mean CFB in PGIS (in patients aged 6 to <12 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
CFB in Observer Reported Global Impression of Severity (OGIS) at all scheduled time points
Aikaikkuna: 0-24 months

Mean CFB in OGIS (in patients aged 2 to <6 years) at all scheduled time points in patients with moderate-to-severe disease treated with abrocitinib

0-24 months
CFB in the the EuroQol- 5 Dimension Youth (EQ-5D-Y)
Aikaikkuna: 0-24 months

Mean CFB in EQ-5D-Y at all scheduled time points in patients with moderate-tosevere AD treated with abrocitinib versus placebo.

0-24 months
Number of topical corticosteroid and /or topical calcineurin inhibitor free days
Aikaikkuna: 0-24 months

Mean number of days free from topical corticosteroids and /or topical calcineurin inhibitor use in patients with moderate-to-severe disease treated with abrocitinib.

0-24 months
Percentage of Participants Achieving satisfactory response in Tdap/DTaP and/or pneumococcal antibody titers as appropriate in participants who receive Tdap/DTaP and/or pneumococcal vaccinations
Aikaikkuna: 0-24 months

For patients that receive Tdap/ DTap and/or pneumococcal vaccinations during the study, the proportion of patients treated with abrocitinib who achieve satisfactory immunogenicity at 4 weeks after receiving the vaccinations.

0-24 months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Tutkijat

  • Opintojohtaja: Pfizer CT.gov Call Center, Pfizer

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Tiistai 2. joulukuuta 2025

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 22. helmikuuta 2032

Opintojen valmistuminen (Arvioitu)

Sunnuntai 22. helmikuuta 2032

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 29. tammikuuta 2025

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Keskiviikko 29. tammikuuta 2025

Ensimmäinen Lähetetty (Todellinen)

Tiistai 4. helmikuuta 2025

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Torstai 5. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 3. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • B7451031
  • 2023-509124-18-00 (Rekisterin tunniste: CTIS (EU))
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .